Updated and reviewed June 2026.

Alpha‑emitter PRRT is emerging as the next major evolution of peptide receptor radionuclide therapy. Instead of using a beta‑emitting isotope such as 177Lu, these new approaches use alpha‑particle–emitting isotopes like 212Pb or 225Ac. The goal is simple: deliver more powerful DNA‑damaging radiation directly into tumour cells while keeping the impact on surrounding tissues as low as possible.

This is still experimental, but the science is compelling — and the early clinical signals are strong enough that alpha‑emitter PRRT is now considered one of the most important areas to watch in NET research.

How alpha‑emitter PRRT works

• Alpha particles deliver extremely high energy over a very short distance (50–100 micrometres).
• This creates dense clusters of double‑strand DNA breaks, which tumour cells struggle to repair.
• The short path length means the radiation stays highly localised, potentially reducing damage to nearby healthy tissue.
• This may help overcome resistance in patients who have progressed after standard Lu‑177 PRRT.

Think of it this way: Beta‑emitter PRRT is a precision rifle. Alpha‑emitter PRRT is a close‑range knockout punch.

The NET‑Focused Clinical Landscape (2024–2026)

This section covers only the alpha‑emitter PRRT programmes that matter right now for NETs and NECs.

1. 212Pb‑DOTAMTATE (AlphaMedix)

212Pb‑DOTAMTATE is currently the most advanced alpha‑emitter PRRT programme in NETs.

Key points:

• Uses lead‑212, which decays to bismuth‑212, the actual alpha emitter.
• Phase 2 results show encouraging response rates in SSTR‑positive NETs.
• Final Phase 2 data will be presented at ESMO 2025.
• A Phase 3 trial is expected to follow.
• Short half‑life may reduce long‑term toxicity.
• Strong rationale for post‑Lu‑177 progression.

This is the alpha‑PRRT candidate most likely to reach regulatory submission first.

1b. 212Pb‑VMT‑α‑NET (Perspective Therapeutics)

Perspective Therapeutics (formerly Viewpoint Molecular Targeting) is developing a second 212Pb‑based alpha‑emitter PRRT programme for NETs. This therapy uses a true theranostic pair: a 203Pb diagnostic agent for imaging and dosimetry, and a 212Pb therapeutic agent for treatment. The company has re‑initiated its Phase 1/2a clinical trial, confirming that this NET‑specific alpha‑PRRT programme remains active. This makes 212Pb‑VMT‑α‑NET one of the few dedicated alpha‑emitter PRRT candidates in clinical development for somatostatin‑receptor–positive NETs.

2. 225Ac‑DOTATATE / 225Ac‑DOTATOC (RYZ101/401)

Actinium‑225–labelled PRRT is being explored in multiple investigator‑initiated studies.

What we know:

• Some patients show excellent tumour responses, including after Lu‑177 progression.
• The major challenge is xerostomia (dry mouth) due to salivary gland uptake.
• Global production of actinium‑225 remains limited, slowing large‑scale trials.
• Despite challenges, 225Ac‑labelled PRRT remains one of the most promising alpha‑PRRT avenues.Note: RYZ101 and RYZ401 are both Actinium‑225–labelled SSTR‑targeted radiopharmaceuticals developed by RayzeBio/BMS. RYZ101 is for PRRT‑pre-treated patients, while RYZ401 is being studied in PRRT‑naïve patients.

Availability outside formal trials (India and Germany)

Some centres in India and Germany now offer 225Ac‑labelled PRRT outside formal clinical trials. These programmes operate under local institutional protocols rather than regulated Phase 1–3 studies.

• India has been offering 225Ac‑PRRT for several years (Delhi and Bengaluru).
• Germany has recently adopted similar approaches in selected nuclear medicine centres.
• These treatments are not approved by EMA, FDA, MHRA, or CDSCO.
• Evidence comes from small case series, not large controlled trials.
• Dosing, toxicity management, and long‑term outcomes vary between centres.

Important: The availability of alpha‑PRRT outside formal trials does not imply endorsement or recommendation. These approaches should always be discussed with your own specialist team, who can help you understand the potential risks, uncertainties, and whether such treatment is appropriate for your individual situation.

This highlights the need for structured global trials to fully understand the benefits and risks of alpha‑emitter PRRT.

3. DLL3‑Targeted Alpha Therapy (MP0712)

This is not SSTR‑based PRRT (i.e. it is not “PRRT” per se — but it is highly relevant for NETs, particularly high‑grade NEC.

• DLL3 is strongly expressed in many high‑grade neuroendocrine carcinomas.
• MP0712 is a DLL3‑targeted 212Pb Radio‑DARPin.
• Expected to enter clinical trials once regulatory registration appears.
• This links directly to your DLL3 expression blog.
• Shows that alpha‑emitter PRRT is not limited to SSTR.

This is potentially a key bridge between NET/NEC biology and the wider theranostics field.

Interest section – PRRT Is Expanding Beyond NETs

Note: Outside neuroendocrine tumours, the term ‘PRRT’ is not technically correct. PRRT refers specifically to somatostatin‑receptor–targeted radionuclide therapy. When similar approaches are used in other cancers — for example PSMA‑targeted therapy in prostate cancer or FAP‑targeted therapy in solid tumours — the broader terms radioligand therapy (RLT) or targeted radionuclide therapy (TRT) are more appropriate. This reflects the fact that PRRT originated in NETs but the underlying theranostic model is now being applied across oncology.

PRRT began in NETs — but it is no longer confined to them.

The same principle — a targeting molecule linked to a therapeutic radionuclide — is now being applied across oncology. Alpha‑emitter PRRT is part of this broader expansion.

Below are emerging targets with clinicaltrials.gov entries, showing how the field is widening.

PSMA (Prostate Cancer)

• Multiple trials for ^225Ac‑PSMA‑617 and other alpha‑PSMA agents.
• Strong responses in metastatic castration‑resistant prostate cancer.
• Demonstrates how alpha therapy can be applied outside NETs.

FAP (Fibroblast Activation Protein)

• FAP is expressed in many solid tumours (pancreatic, colorectal, breast, sarcoma).
• Several trials exist for FAP‑targeted radioligands, including alpha‑labelled constructs.
• A major direction for future theranostics.

CXCR4

• Trials exist for CXCR4‑directed radioligands (beta and alpha).
• Relevant for haematologic malignancies and dedifferentiated solid tumours.
• Shows how alpha therapy may reach aggressive tumour types.

HER2, GRPR and others

• Early alpha‑labelled constructs exist with trial entries.
• These targets broaden the reach of PRRT‑style therapy into breast, gastric, and prostate cancers.

2023 Alpha‑Emitter Clinical Trials Review

A 2023 review by Jang et al. summarised alpha‑particle clinical trials across oncology, including but not limited to NETs. The review highlights trials involving PSMA, FAP, CXCR4, HER2, GRPR and other targets, demonstrating how alpha‑emitter therapy is being applied far beyond somatostatin‑receptor–positive disease.

Reference: Jang, A.; Kendi, A.T.; Johnson, G.B.; Halfdanarson, T.R.; Sartor, O. Targeted Alpha‑Particle Therapy: A Review of Current Trials. Int. J. Mol. Sci. 2023, 24, 11626.

Challenges and Considerations

Alpha‑emitter PRRT is powerful — but not simple.

• Toxicity
  • Salivary glands
  • Kidneys
  • Bone marrow
• Isotope supply
  • Actinium‑225 and lead‑212 production is still limited.
• Imaging limitations
  • Alpha emitters cannot be imaged directly; surrogate isotopes are needed.
• Dosimetry
  • Alpha dosimetry is more complex and less standardised.
• Tumour heterogeneity
  • Not all lesions express SSTR equally.

These challenges explain why alpha‑emitter PRRT is not yet routine clinical practice.

The Future of Alpha‑Emitter PRRT

The next 3–5 years will likely bring:

• Alpha imaging surrogates (e.g., 203Pb for 212Pb)
• Combination therapy
  • Alpha + beta PRRT
  • Alpha PRRT + immunotherapy
• Improved chelators to reduce off‑target toxicity
• Better salivary gland protection strategies
• Personalised alpha dosimetry
• More global trials, including multi‑centre Phase 3 studies

This is a rapidly evolving field — but NETs remain at the centre of it. The DLL-3 trial indicates NEC is being considered.

What This Means for Patients

Alpha‑emitter PRRT is one of the most exciting developments in NET therapy. But it is still early.

The science is strong. The rationale is compelling. The first clinical results are promising.

But we need:

• larger trials
• longer follow‑up
• better toxicity management
• more reliable isotope supply

For now, think of alpha‑emitter PRRT as the next chapter — not a replacement for existing PRRT, but a potential option for the future, especially for those who have exhausted standard therapies.

Resources

Active or Recent Clinical Trials (Alpha‑Emitter PRRT and Related Radioligand Therapies)

NET‑Focused Alpha‑Emitter PRRT Trials

• NCT05153772 — 212Pb‑DOTAMTATE (AlphaMedix) Phase 2 study in SSTR‑positive NETs.
• NCT03466216 — 212Pb‑VMT‑α‑NET (Perspective Therapeutics) Phase 1/2a theranostic trial using ^203Pb/212Pb pair.
• NCT06166498 — ^25Ac‑DOTATATE (Investigator‑Initiated) Early‑phase study exploring actinium‑225 PRRT in NETs.

High‑Grade NEC / DLL3‑Targeted Alpha Therapy

• MP0712 (DLL3‑212Pb) — Trial number pending Expected to appear on ClinicalTrials.gov once regulatory registration is complete. Links to my DLL3 expression article.

Radioligand Therapy Beyond NETs (i.e. Alpha‑Emitter Trials in Other Cancers)

Prostate Cancer (PSMA‑Targeted Radioligand Therapy)

• NCT04597411 — 225Ac‑PSMA‑617
• NCT05219500 — 225Ac‑PSMA‑I&T

FAP‑Targeted Radioligand Therapy

• NCT05653882 — FAP‑targeted alpha therapy

CXCR4‑Targeted Radioligand Therapy

• NCT05117772 — CXCR4‑targeted alpha therapy

HER2 / GRPR and Other Targets

• NCT05262543 — HER2‑targeted alpha therapy
• NCT05370657 — GRPR‑targeted alpha therapy

Key Scientific and Review Articles

2025 Review: Clinical Experience with Alpha‑Emitter PRRT in NETs

A comprehensive 2025 review summarising all available clinical evidence for alpha‑emitter PRRT in somatostatin‑receptor–positive NETs, including 225Ac‑DOTATATE, 212Pb‑DOTAMTATE, and 212Pb‑VMT‑α‑NET. It provides pooled response rates, toxicity profiles, and insights into patient selection.

Reference: Leupe H, Cauwenbergh M, Cleeren F, et al. Clinical Experience with Targeted Alpha‑Emitter Peptide Receptor Radionuclide Therapy (α‑PRRT) for Somatostatin Receptor‑Positive Neuroendocrine Tumors. Pharmaceuticals. 2025;18(11):1608. PMCID: PMC12655202.

Summarise this review

2023 Alpha‑Emitter Clinical Trials Review (includes beyond NETs)

Reference: Jang, A.; Kendi, A.T.; Johnson, G.B.; Halfdanarson, T.R.; Sartor, O. Targeted Alpha‑Particle Therapy: A Review of Current Trials. Int. J. Mol. Sci. 2023, 24, 11626.

Patient‑Focused Guidance

• Discuss all alpha‑PRRT options with your specialist team – Alpha‑emitter PRRT remains experimental. Availability in India or Germany does not imply endorsement or suitability. Talk to your specialist

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted.  Please check any references attached.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.

Finally

Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product.  Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document.   Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET

Click here to enter Ronny’s Clinical Trials Archive

Thanks for reading.

Select a category of posts you’d like to see

• A spotlight on NENs
• A spotlight on NENs – Syndromes
• A Spotlight on NENs – Testing Series
• A spotlight on NENs – Types
• Awareness
• Clinical Trials and Research
• Diet and Nutrition
• Fundraising
• General
• Humour
• Inspiration
• Latest ENETS Guidelines
• Living with Neuroendocrine Cancer
• Newsletters
• Patient Advocacy
• Ronny Allan’s “The Trouble with the NET Series”
• Sometimes you gotta climb that hill!
• Spotlight on NENs – Types Series
• Survivorship
• The NET Effect Series
• Travel with Ronny
• Treatment

Click here and answer all questions to join my private Facebook group

Thanks for reading.

Ronny

 

Check out my WEGO Health Awards

Check out my Glossary of Terms – click here

Please Share this post for Neuroendocrine Cancer awareness and to help other patients